ADC Therapeutics SA
ADCT
$1.89
$0.2011.83%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.59% | 0.71% | 27.40% | -9.71% | -4.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.59% | 0.71% | 27.40% | -9.71% | -4.94% |
| Cost of Revenue | -17.89% | -11.98% | 404.66% | -21.44% | 9,396.30% |
| Gross Profit | 34.93% | 13.94% | 17.65% | 38.58% | -18.28% |
| SG&A Expenses | -12.44% | -17.24% | -11.47% | -20.86% | -24.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.33% | -13.07% | 6.69% | -21.18% | -25.34% |
| Operating Income | 15.32% | 18.87% | 1.62% | 26.75% | 33.06% |
| Income Before Tax | 17.24% | 25.83% | 6.26% | 32.03% | 21.09% |
| Income Tax Expenses | 1.23% | -100.74% | 205.88% | 105.20% | -68.53% |
| Earnings from Continuing Operations | 17.17% | 63.86% | 5.90% | 25.30% | 21.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.17% | 63.86% | 5.90% | 25.30% | 21.50% |
| EBIT | 15.32% | 18.87% | 1.62% | 26.75% | 33.06% |
| EBITDA | 15.50% | 19.04% | 1.69% | 27.07% | 33.37% |
| EPS Basic | 36.22% | 71.79% | 26.14% | 36.40% | 23.16% |
| Normalized Basic EPS | 36.26% | 42.09% | 26.45% | 42.12% | 22.76% |
| EPS Diluted | 36.22% | 71.79% | 26.14% | 36.40% | 23.16% |
| Normalized Diluted EPS | 36.26% | 42.09% | 26.45% | 42.12% | 22.76% |
| Average Basic Shares Outstanding | 29.86% | 28.08% | 27.44% | 17.45% | 2.16% |
| Average Diluted Shares Outstanding | 29.86% | 28.08% | 27.44% | 17.45% | 2.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |